Cardiac disease in chronic kidney disease: Current understandings and opportunities for change

Blood Purification

Volumn 22, Issue 1, 2004, Pages 21-27

  Levin, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiovascular disease; Chronic kidney disease; Pathophysiology; Risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCIENCE;

ANEMIA; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COMORBIDITY; DIABETES MELLITUS; ENDOTHELIAL CELLS; HUMANS; KIDNEY FAILURE, CHRONIC; MINERALS; MULTICENTER STUDIES; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS;

EID: 0942268188     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074920     Document Type: Review

References (57)

1. Levin A, Singer S, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
2. Levin A, Thompson C, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
3. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
4. Harnett JD, Foley RN, Kent GM, et al: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890.
5. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002;13:1084-1090.
6. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000;35(4 suppl 1):S117-S131.
7. Foley RN, Parfrey PS, Harnett JD, et al: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
8. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
9. Kovesdy CP, Astor BC, Longenecker JC, Coresh J: Association of kidney function with serum lipoprotein(a) level: The third National Health and Nutrition Examination Survey (1991-1994). Am J Kidney Dis 2002;40:899-908.
10. Block GA, Hulbert-Shearon T, Levin N, Port F: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617.
11. 4) product, and para-thyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
12. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, Levey AS, Sarnak MJ: Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42:44-52.
13. Suliman ME, Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B: Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: Influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 2003;41(3 suppl 1):S89-S95.
14. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G: Reduced capillary density in the myocardium of uremic rats - A stereological study. Kidney Int 1992;42:1079-1085.
15. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022.
16. Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-141.
17. Malatino L, Mallamaci F, Benedetto FA: Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. Am J Kidney Dis 2000;36:945-952.
18. Noris M, Remuzzi G: Physiology and pathophysiology of nitric oxide in chronic renal disease (review). Proc Assoc Am Physicians 1999;111:602-610.
19. Ketteler M, Wanner C, Metzger T, Bongartz P, Westenfeld R, Gladziwa U, Schurgers LJ, Vermeer C, Jahnen-Dechent W, Floege J: Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 2003;(84):S84-S87.
20. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003;361:827-833.
21. Culleton BF, Hemmelgarn BR: Is chronic kidney disease a cardiovascular risk factor? Semin Dial 2003;16:95-100.
22. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129.
23. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
24. Wright RS, Reeder GS, Herzog CA, et al: Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 2002;137:563-570.
25. Shlipak MG, Heidenreich PA, Nocughi H, et al: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-562.
26. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, et al: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-962.
27. Mann JFE, Gerstein HC, Pogue J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001;134:629-636.
28. Szczech LA, Best PJ, Crowley E, et al: Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 2002;105:2253-2258.
29. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119.
30. Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002;106:2207-2211.
31. Hemmelgarn BR, Ghali WA, Quan H, et al: Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 2001;37:64-72.
32. McClellan W, Flanders W, Langston R, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 2002;13:1928-1936.
33. Tuttle KR, Puhlman ME, Cooney SK, Short R: Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis 1999;34:918-925.
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
35. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
36. Collins A, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473.
37. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, Handa SP, Jindal KK, Kjellstrand CM, Levin A, Mandin H, Muirhead N, Richardson RM: Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 1997;29:214-222.
38. Levin A, Djurdjev O, Barrett B, et al: Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-1407.
39. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002;13:1084-1090.
40. Rigatto C, Foley R, Kent G, et al: Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000;70:570-575.
41. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
42. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
43. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley Cl, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: The effect of early and late intervention with epoetin alfa on left ventricular mass in patients with chronic kidney disease: Results of a randomized clinical trial. J Am Soc Nephrol, accepted.
44. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-361.
45. Ofshun N, LeBrecque J, Lacson E, Keen M, Lazarua JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003;63:1908-1914.
46. Avram M, Mittman N, Myint M, Fein P: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001;38:1351-1357.
47. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
48. Moe S, O'Neill K, Duan D, Ahmed S, Chen N, Leapman S, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-647.
49. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
50. Raggi P: Imaging of cardiovascular calcifications with electron beam tomography in hemodialysis patients. Am J Kidney Dis 2001;37(1 suppl 2):S62-S65.
51. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R 3rd: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979;66:790-796.
52. Chen NX, O'Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
53. Davies M, Hruska K: Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-479.
54. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
55. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002;287:548-555.
56. Blacher J, Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM, et al: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-1860.
57. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001;37:484-489.